LY294002 decreases the proliferation of cancer stem cell-enriched spheroid cells from human hepatocellular carcinoma via inhibiting of PI3K-Akt signaling pathway

Abstract

Abstract:ObjectiveTo investigate the impact of LY294002 on the proliferation of cancer stem cellenriched spheroid cells from human hepatocellular carcinoma via regulating phosphatidylinositol3kinaseprotein kinase B (PI3KAkt) signaling pathway.MethodsThe cancer stem cellenriched spheroid cells were generated by culturing HepG2 cells in serumfree medium. LY294002 (10, 20, 30 μmol/L), an inhibitor of PI3KAkt signaling pathway, was used in the experimental groups, without used in the control group. The impact of LY294002 on the spheroid cells proliferation was confirmed by cell counting kit (CCK8 kit). The expression of Akt was tested by Western blotting. The expression of PI3KAkt signaling pathway downstream genes such as decoy receptor 3 (DcR3), mammalian target of rapamycin (mTOR), Bcell lymphoma (Bcl)2 and Cyclin D1 were tested by realtime PCR.Results30 μmol/L LY294002 could inhibit the proliferation of spheroid cells, and significant difference in the absorbance (A value) was observed between the experimental group and control group［(0.14±0.03) vs (0.56±0.01), t=-8.915, P=0.000］. The expression level of phosphorylated Akt protein increased［(0.57±0.08) vs (0.16±0.42), t=6.027, P=0.026］. The mRNA of DcR3［(0.38±0.08) vs 1, t=13.060, P=0.006］, mTOR［(0.37±0.04) vs 1, t=30.363, P=0.001］, Bcl2［(0.26±0.04) vs 1, t=33.554, P=0.001］ and Cyclin D1［(0.10±0.02) vs 1, t=63.528, P=0.000］ decreased.ConclusionLY294002 could inhibit the proliferation of cancer stem cellenriched spheroid cells from human hepatocellular carcinoma via inhibiting PI3KAkt signaling pathway.

Key words:Liver neoplasms,Neoplastic stem cells,Signal transduction,Spheroid cells

LENG ZhengWei；Yang Gang；Li Yong；Shi-Gang. LY294002 decreases the proliferation of cancer stem cell-enriched spheroid cells from human hepatocellular carcinoma via inhibiting of PI3K-Akt signaling pathway[J]. Journal of International Oncology, 2015, 42(4): 241-244.

References

［1］ Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities［J］. Cell Stem Cell, 2012,10(6): 717728. ［2］ Nguyen LV, Vanner R, Dirks P, et al. Cancer stem cells: an evolving concept［J］. Nat Rev Cancer, 2012,12(2): 133143. ［3］ Leng Z, Tao K, Xia Q, et al. Kruppellike factor 4 acts as an oncogene in colon cancer stem cellenriched spheroid cells［J］. PLoS One, 2013,8(2): e56082. ［4］ Cao L, Zhou Y, Zhai B, et al. Sphereforming cell subpopulations with cancer stem cell properties in human hepatoma cell lines［J］. BMC Gastroenterol, 2011,11: 71. ［5］ Deng L, Zhang R, Tang F, et al. Ursolic acid induces U937 cells differentiation by PI3K/Akt pathway activation［J］. Chin J Nat Med, 2014,12(1): 1519. ［6］ Kantara C, O′Connell M, Sarkar S, et al. Curcumin promotes autophagic survival of a subset of colon cancer stem cells, which are ablated by DCLK1siRNA［J］. Cancer Res, 2014,74(9): 24872498. ［7］ Ponti D, Costa A, Zaffaroni N, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties［J］. Cancer Res, 2005,65(13): 55065511. ［8］ Wei B, Han XY, Qi CL, et al. Coaction of spheroidderived stemlike cells and endothelial progenitor cells promotes development of colon cancer［J］. PLoS One, 2012,7(6): e39069. ［9］ Liu J, Ma L, Xu J, et al. Spheroid bodyforming cells in the human gastric cancer cell line MKN45 possess cancer stem cell properties［J］. Int J Oncol, 2013,42(2): 453459. ［10］ Yang T, Rycaj K, Liu ZM, et al. Cancer stem cells: constantly evolving and functionally heterogeneous therapeutic targets［J］. Cancer Res, 2014,74(11): 29222927. ［11］ Tomuleasa C, Soritau O, RusCiuca D, et al. Isolation and characterization of hepatic cancer cells with stemlike properties from hepatocellular carcinoma［J］. J Gastrointestin Liver Dis, 2010,19(1): 6167. ［12］ Zhu Z, Hao X, Yan M, et al. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma［J］. Int J Cancer, 2010,126(9): 20672078. ［13］ Terris B, Cavard C, Perret C. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma［J］. J Hepatol, 2010,52(2): 280281. ［14］ Zheng L, Gong W, Liang P, et al. Effects of AFPactivated PI3K/Akt signaling pathway on cell proliferation of liver cancer［J］. Tumour Biol, 2014,35(5): 40954099. ［15］姜蓬垒, 常冰梅. PI3KAkt信号通路与肿瘤化疗耐药性［J］. 国际肿瘤学杂志, 2014, 41(5)： 324327. ［16］ Jiang QG, Li TY, Liu DN, et al. PI3K/Akt pathway involving into apoptosis and invasion in human colon cancer cells LoVo［J］. Mol Biol Rep, 2014, 41(5): 33593367. ［17］ Wang XJ, Feng CW, Li M. ADAM17 mediates hypoxiainduced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway［J］. Mol Cell Biochem, 2013,380(12): 5766.

[1]	Wei Yongjian, Hu Jinjing, Li Xun.Relationship between CDCA8 and tumor progression as well as that between CDCA8 and stemness maintenance of stem cells[J]. Journal of International Oncology, 2021, 48(4): 216-219.
[2]	Kang Ye, Li Jianyi, Yang Xianghong.Research progress of cancer stem cells in triplenegative breast cancer[J]. Journal of International Oncology, 2019, 46(6): 362-365.
[3]	XU Yao-Zong, GU Xiao, WANG Fei, DING Xue-Fei.Molecular mechanisms of castrationresistant prostate cancer progressed from prostate cancer by androgen deprivation treatment[J]. Journal of International Oncology, 2018, 45(8): 506-509.
[4]	Du Jingquan*, Guo Xiaoling, Wei Yongli, Li Keming, Yu Hao.Network pharmacology based study on mechanism of peony leaf in the treatment of cervical cancer[J]. Journal of International Oncology, 2018, 45(8): 519-524.
[5]	Zhang Yuanyuan, Zhu Shuxia.Mechanism of microRNA-495 in glioma[J]. Journal of International Oncology, 2018, 45(6): 362-364.
[6]	Liu Hengyao, Zhao Guoli, Wang Fuwen, Cai Haibo, Zhang Yueying..Notch signaling pathway in lung cancer and lung cancer stem cells and its inhibitors[J]. Journal of International Oncology, 2018, 45(4): 250-252.
[7]	Xing Rongchun， Qin Zhouping.Study on cell matrix of pancreatic duct adenocarcinoma[J]. Journal of International Oncology, 2018, 45(11): 696-698.
[8]	PENG Yong-Hua, PENG Li, LIANG Zhi-Man, ZHANG Xing-Mei.Application of aptamer in the study of cancer stem cells[J]. Journal of International Oncology, 2017, 44(8): 672-675.
[9]	Tong Yalan, Han Tao, Liu Zhongzheng, Yuan Gang, Liang Yan, Liu Zhaozhe, Xie Xiaodong, Yue Chengshan.Therapeutic resistance of breast cancer stem cells and its related signaling pathway[J]. Journal of International Oncology, 2017, 44(7): 544-546.
[10]	Sun Fei, Wang Jianlin, Yu Jingping.Research advances of cancer therapy targeting HIF-1α-VEGF-VEGFR-2 signaling pathway for malignant tumors[J]. Journal of International Oncology, 2017, 44(6): 456-.
[11]	Yang Feilong, Li Dawei, Ren Juchao, Yan Lei, Zhou Zunlin, Liu Hainan, Xu Zhonghua.Expression of hepatomaderived growth factor in tumor and its related signaling pathway[J]. Journal of International Oncology, 2017, 44(3): 193-195.
[12]	Guo Chongyong, Li Yongmei, Li Bocheng, Zhou Ling, Zhang Jian, Jia Zongshi.Expressions and clinical significances of aldehyde dehydrogenase 1 and transforming growth factor-β2 in triple negative breast cancer[J]. Journal of International Oncology, 2017, 44(11): 801-805.
[13]	郑佩.Wnt/β-catenin signaling pathway and cancer stem cells[J]. Journal of International Oncology, 2017, 44(11): 853-855.
[14]	Wang Hao, Zhang Qingling.PI3K signaling pathway in colorectal cancer[J]. Journal of International Oncology, 2016, 43(8): 631-633.
[15]	GAN Ya-Ping, GUO Xiao-Hua, ZHANG Jun-Yu, XU Qing-Qing, WU Jiang, WANG Ren-Yong, QIU Min, JIANG Ru-Gang, LIU Fu-Xing, NING Zhi-Feng.Construction of colonic cancer drugresistant cell line COLO and its relationship with tumor stem cells[J]. Journal of International Oncology, 2016, 43(8): 646-650.